Targeting FGF19 holds therapeutic potential for modulating tumor metabolism by inhibiting the FGFR4-ERK pathway, thereby reducing the expression of key fatty acid synthesis enzymes, such as FASN and ACC, and ultimately disrupting the metabolic support for tumor proliferation. This evidence concerns the gene FGF19 and neoplasm.